CLAIMS

1. Use of chimeric, humanised or human class IgG3 monoclonal antibodies produced in a cell line of rat myeloma, particularly YB2/0 (ATCC No. CRL 1662) or a derived or modified line of YB2/0 for preparation of a medicine for the treatment of different cancer and infectious pathologies.

2. Use according to claim 1, characterised in that it relates to patients with a weak response to treatment with an IgG1 or an IgG3 expressed in CHO.

3. Use according to either claim 1 or 2, characterised in that it is used in patients with a late diagnosis.

4. Use according to any one of the previous claims, characterised in that the said cancer pathologies are chosen from among the group comprising neuroectodermal tumours, colorectal cancers, melanomas, breast cancer, leukaemia and particularly HCL (Hairy Cell Leukaemia), lymphomas such as DLBCL (Primary Diffuse Large B-Cell Lymphomas), acute leukaemias, osteosarcomas.

5. Use according to any one of the previous claims, characterised in that the said cancer pathologies are associated with viral or bacterial infections.

6. Use according to claim 5, characterised in that the said infections with viral or bacterial origin are chosen from among the group comprising cancer of the prostate, leukaemias and Kaposi's sarcoma.

7. Use according to any one of claims 1 to 3, characterised in that the said infectious pathologies are chosen from the group including diphtheria, viral hemorrhagic fevers, typhoid fever, influenza, hepatitis B and C, respiratory infections due to RSV, infections due to HIV,

legionnaires' disease, Leishmaniasis, leprosy, rabies, AIDS or tuberculosis.

8. Use according to any one of the previous claims, for the capability of the said antibody to induce a phagocytosis.

9. Use according to any one of the previous claims, characterised in that the said medicine is intended to be used in combination with an IgG1.

10. Use according to any one of the previous claims, for the capability of the said antibody to negatively modulate the release of cytokines induced by IgG1, and particularly the contents of gamma IFN, alpha TNF and/or IL6.

11. Use according to either claim 9 or 10, for the preparation of a medicine for the treatment of cancer pathologies in patients with a "cytokine release syndrome".

12. Use according to claim 11, for the preparation of a medicine to treat patients suffering from hypothermia, acute renal necrosis and diseases of the liver due to "cytokine release syndrome".

13. Use according to either claim 11 or 12, characterised in that the said "cytokine release syndrome" has been induced by the administration of an anti-CD3 monoclonal antibody.

14. Use according to either claim 11 or 12, characterised in that the said class IgG3 antibody is an anti-CD20, to prevent the appearance of the "cytokine release syndrome" in patients treated with Rituximab® (IDEC-C2B8).

15. Use according to either claim 11 or 12, to prevent the undesirable effects of the CAMPATH® or OKT3 antibody.

16. Process for modulating the release of cytokines induced by an IgG1, characterised in that IgG3s produced in a cell line of rat myeloma, particularly YB2/0, are added to the biological system containing the said IgG1s.

17. Process according to claim 16, characterised in that the said IgG1s are produced in a cell line of rat myeloma, particularly YB2/0.

18. Pharmaceutical composition of therapeutic antibodies comprising IgG1s, IgG3s and at least one excipient.

19. Composition according to claim 18, characterised in that at least one of the said IgGs is produced in a cell line of rat myeloma, and particularly YB2/0.